CRSP logo

CRISPR TherapeuticsNasdaqGM:CRSP Stock Report

Market Cap US$6.0b
Share Price
US$68.14
My Fair Value
AN
AnalystConsensusTarget
US$82
16.7% undervalued intrinsic discount
1Y23.0%
7D23.6%
Portfolio Value
View

CRISPR Therapeutics AG

NasdaqGM:CRSP Stock Report

Market Cap: US$6.0b

CRISPR Therapeutics (CRSP) Stock Overview

A gene editing company, focuses on developing gene-based medicines for serious human diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. More details

CRSP fundamental analysis
Snowflake Score
Valuation3/6
Future Growth2/6
Past Performance0/6
Financial Health5/6
Dividends0/6

CRSP Community Fair Values

Create Narrative

See what 196 others think this stock is worth. Follow their fair value or set your own to get alerts.

CRISPR Therapeutics AG Competitors

Price History & Performance

Summary of share price highs, lows and changes for CRISPR Therapeutics
Historical stock prices
Current Share PriceUS$68.14
52 Week HighUS$71.13
52 Week LowUS$30.04
Beta1.82
1 Month Change49.59%
3 Month Change74.23%
1 Year Change23.02%
3 Year Change-13.67%
5 Year Change-20.33%
Change since IPO383.61%

Recent News & Updates

Crispr Therapeutics: Shares Are Soaring - This Could Be The Start Of Something Big

Jul 23

CRISPR Therapeutics (NASDAQ:CRSP) Is In A Good Position To Deliver On Growth Plans

Mar 27
CRISPR Therapeutics (NASDAQ:CRSP) Is In A Good Position To Deliver On Growth Plans

CRISPR Therapeutics: An Uninspiring Start For Casgevy

Mar 14

Recent updates

Crispr Therapeutics: Shares Are Soaring - This Could Be The Start Of Something Big

Jul 23

CRISPR Therapeutics (NASDAQ:CRSP) Is In A Good Position To Deliver On Growth Plans

Mar 27
CRISPR Therapeutics (NASDAQ:CRSP) Is In A Good Position To Deliver On Growth Plans

CRISPR Therapeutics: An Uninspiring Start For Casgevy

Mar 14

Crispr Therapeutics Q4 Earnings Review: Ignore The Lack Of Revenues, Buy The Future

Feb 13

CRISPR Therapeutics: Unfairly Punished By The Issues Of Its Peers

Jan 16

CRISPR Therapeutics AG's (NASDAQ:CRSP) Share Price Not Quite Adding Up

Dec 31
CRISPR Therapeutics AG's (NASDAQ:CRSP) Share Price Not Quite Adding Up

Crispr Therapeutics: From Casgevy Success To A Catalyst-Rich 2025

Dec 29

Here's Why We're Not Too Worried About CRISPR Therapeutics' (NASDAQ:CRSP) Cash Burn Situation

Dec 03
Here's Why We're Not Too Worried About CRISPR Therapeutics' (NASDAQ:CRSP) Cash Burn Situation

Crispr Therapeutics Q3 Earnings: No Casgevy Revenue, But Plenty Of Optimism

Nov 11

Here's What Analysts Are Forecasting For CRISPR Therapeutics AG (NASDAQ:CRSP) After Its Third-Quarter Results

Nov 07
Here's What Analysts Are Forecasting For CRISPR Therapeutics AG (NASDAQ:CRSP) After Its Third-Quarter Results

Crispr Therapeutics: Poised For A Major Turnaround

Oct 28

CRISPR Therapeutics AG (NASDAQ:CRSP) Investors Are Less Pessimistic Than Expected

Oct 02
CRISPR Therapeutics AG (NASDAQ:CRSP) Investors Are Less Pessimistic Than Expected

Crispr Therapeutics: Casgevy Now Active Across 35 Treatment Centres

Sep 13

Here's Why We're Not At All Concerned With CRISPR Therapeutics' (NASDAQ:CRSP) Cash Burn Situation

Sep 04
Here's Why We're Not At All Concerned With CRISPR Therapeutics' (NASDAQ:CRSP) Cash Burn Situation

Crispr's Casgevy Launch: Promising Start, Uncertain Future

Aug 14

A Look At The Intrinsic Value Of CRISPR Therapeutics AG (NASDAQ:CRSP)

Aug 09
A Look At The Intrinsic Value Of CRISPR Therapeutics AG (NASDAQ:CRSP)

Crispr Therapeutics Q2 Earnings: Casgevy Updates Underline 'Blockbuster' Potential

Aug 07

Crispr Therapeutics Remains Expensive, With Slower Casgevy Monetization And Patent Battle

Jul 13

Crispr Therapeutics: Beaten Down But Not Broken

Jul 07

Crispr Therapeutics, Futurism-Turning-Commercial, Defies 'Valuation' (Technical Analysis)

Jun 10

Crispr Therapeutics' Strategic Moves Amidst Gene Therapy Challenges (Rating Upgrade)

Jun 03

Crispr Therapeutics Q1 Earnings: Casgevy Launch Tip Of Gene Editing Iceberg

May 09

Crispr Therapeutics: Market Misunderstanding Is Your Buying Opportunity (Upgrade)

May 03

Crispr Therapeutics: Now Is The Time To Buy

Apr 24

Crispr Therapeutics: CASGEVY Commercial Launch Is Taking Shape

Mar 26

Crispr Therapeutics: Cautiously Optimistic

Feb 22

Crispr Therapeutics: Investors Bet Against Casgevy Uptake

Feb 01

Crispr Therapeutics: Commercial Validation Is The Next Step

Jan 18

Impact Of Gene Therapies And Casgevy On Crispr AG And The Industry

Jan 11

Shareholder Returns

CRSPUS BiotechsUS Market
7D23.6%2.3%1.7%
1Y23.0%-9.5%17.7%

Return vs Industry: CRSP exceeded the US Biotechs industry which returned -9.5% over the past year.

Return vs Market: CRSP exceeded the US Market which returned 17.7% over the past year.

Price Volatility

Is CRSP's price volatile compared to industry and market?
CRSP volatility
CRSP Average Weekly Movement9.4%
Biotechs Industry Average Movement11.5%
Market Average Movement6.3%
10% most volatile stocks in US Market17.2%
10% least volatile stocks in US Market3.0%

Stable Share Price: CRSP has not had significant price volatility in the past 3 months compared to the US market.

Volatility Over Time: CRSP's weekly volatility (9%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
2013393Sam Kulkarniwww.crisprtx.com

CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious human diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. The company’s CRISPR/Cas9 is a revolutionary technology for gene editing which is the process of precisely altering specific sequences of genomic DNA. It has a portfolio of therapeutic programs across a range of disease areas, including hemoglobinopathies, CAR T cell therapies, in vivo, and type 1 diabetes, as well as develops investigational CAR T programs, including an autologous, gene-edited CAR T program targeting glypican-3 (GPC3) for the potential treatment of solid tumors.

CRISPR Therapeutics AG Fundamentals Summary

How do CRISPR Therapeutics's earnings and revenue compare to its market cap?
CRSP fundamental statistics
Market capUS$6.05b
Earnings (TTM)-US$385.66m
Revenue (TTM)US$37.68m
165.9x
P/S Ratio
-16.2x
P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
CRSP income statement (TTM)
RevenueUS$37.68m
Cost of RevenueUS$437.76m
Gross Profit-US$400.08m
Other Expenses-US$14.43m
Earnings-US$385.66m

Last Reported Earnings

Mar 31, 2025

Next Earnings Date

n/a

Earnings per share (EPS)-4.20
Gross Margin-1,061.93%
Net Profit Margin-1,023.64%
Debt/Equity Ratio0%

How did CRSP perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/07/23 11:25
End of Day Share Price 2025/07/23 00:00
Earnings2025/03/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

CRISPR Therapeutics AG is covered by 48 analysts. 25 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Jack AllenBaird
Huidong WangBarclays
Konstantinos BiliourisBMO Capital Markets Equity Research